Total Funding
Total FundingSeed raised
Growth Score
pts
Heat Score
pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Anviro is a broad-spectrum antiviral company that develops treatments for some of the world’s most problematic infectious diseases.
- Matthew Cryer: CEO
About the Company
Anviro Therapeutics is a broad-spectrum antiviral company that develops treatments for some of the world’s most problematic infectious diseases, including pox viruses and herpes viruses. Its lead program is based on technology discovered by researchers at Brigham Young University (BYU). This compound, designated KPB-100, was found to have powerful
antiviral properties and efficacy across a wide range of viruses in herpes and pox virus families.
In April of 2015, Anviro licensed this technology from BYU and are in the process of medicinal optimization and animal model validation.
